Table S1. Summary of guideline recommendations in WD.

Society guidelines	Diagnosis				Treatment				Special circumstances
	Diagnostic testing	Diagnosis of ALF due to WD	Family screening		Medical therapy	Treatment monitoring	Transplant		ALF	Pregnancy	Surgery
AASLD 2008	Clinical and biochemical algorithmic approach	Laboratory and clinical assessment	Siblings: genetic testing*. Children, other first-degree relatives: clinical assessment		Initial: chelator +/− zinc. Maintenance and asymptomatic: chelator or zinc	24-hour urine copper	Indication: decompensated cirrhosis, not primarily for neuropsychiatric disease		Bridging therapies, transplant	Dose-reduction of chelator, no adjustment for zinc	Dose-reduction of chelator, no adjustment for zinc
EASL 2012	Leipzig score	Laboratory and clinical assessment	First-degree relatives: genetic testing		Initial: chelator. Maintenance and asymptomatic: chelator or zinc	24-hour urine copper	Indication: decompensated cirrhosis, not primarily for neuropsychiatric disease. Prognosis: revised King’s Wilson score		Transplant	Dose-reduction of chelator, no adjustment for zinc	–
ESPGHAN 2018	Clinical and biochemical algorithm and Leipzig score	Laboratory and clinical assessment	First-degree relatives: clinical assessment and genetic testing*		Initial: chelator +/− zinc. Maintenance and asymptomatic: zinc	24-hour urine copper. If zinc therapy: serum zinc, 24-hour urine zinc	Indication: decompensated cirrhosis, exclude severe neuropsychiatric disease. Prognosis: revised King’s Wilson score		Bridging therapies, transplant	–	–

*, if genetic testing unavailable, standard biochemical and clinical testing. WD, Wilson disease.